Detailed Study of the Psoriasis - Pipeline Review, H2 2016
Psoriasis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Psoriasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.
To view the table of contents and know more details please visit Psoriasis - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psoriasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc Abeome Corporation AbGenomics International, Inc. Addex Therapeutics Ltd Advinus Therapeutics Ltd Affibody AB Albireo AB Almirall, S.A. Alteogen Inc. Amgen Inc. Anacor Pharmaceuticals, Inc. AnaptysBio, Inc. ApoPharma Inc. Arena Pharmaceuticals, Inc. Argos Therapeutics, Inc. Arrien Pharmaceuticals, LLC AstraZeneca Plc Athenex, Inc. Aurigene Discovery Technologies Limited Aurinia Pharmaceuticals Inc Avexxin AS Betta Pharmaceuticals Co. Ltd. BioApex, s.r.o. BIOCAD Biocon Limited BioLingus AG BioMAS Ltd. Biomics Biotechnologies Co., Ltd. Bionomics Limited Bionovis SA Boehringer Ingelheim GmbH Brickell Biotech, Inc. Bristol-Myers Squibb Company C4X Discovery Holdings PLC CalciMedica, Inc. Can-Fite BioPharma Ltd. Celgene Corporation Cell Medica Limited Cellceutix Corporation ChemoCentryx, Inc. Chipscreen Biosciences Ltd ChironWells GmbH Clonz Biotech Private Limited Coherus BioSciences, Inc. etc,.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:41
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home